Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma

Kimberly A. Noonan, Nilanjan Ghosh, Lakshmi Rudraraju, Marilyn Bui, Ivan Borrello

Research output: Contribution to journalArticlepeer-review


Myeloid-derived suppressor cells (MDSC) play a significant role in tumor-induced immune suppression. Targeting their function could improve antitumor therapies. Previously, we demonstrated that phosphodiesterase 5 (PDE5) inhibition in MDSCs augmented antitumor immunity in murine models. Here, we show how the addition of the PDE5 inhibitor, tadalafil, in a patient with end-stage relapsed/refractory multiple myeloma reduced MDSC function and generated a dramatic and durable antimyeloma immune and clinical response. Strategies targeting MDSC function with PDE5 inhibitors represent a novel approach that can augment the efficacy of tumor-directed therapies.

Original languageEnglish (US)
Pages (from-to)725-731
Number of pages7
JournalCancer Immunology Research
Issue number8
StatePublished - Aug 1 2014

ASJC Scopus subject areas

  • Immunology
  • Cancer Research


Dive into the research topics of 'Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma'. Together they form a unique fingerprint.

Cite this